USFDA12 Nov 2025, 10:34 pm
Lupin Ltd Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility
AI Summary
Global pharma major Lupin Limited has announced receiving the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility. The EIR follows a product-specific Pre-Approval Inspection conducted from September 1 to September 5, 2025. Nilesh Gupta, Lupin's Managing Director, expressed satisfaction, stating that this underscores Lupin's commitment to quality, compliance, and delivering trusted healthcare solutions to patients worldwide.
Key Highlights
- Lupin Ltd receives EIR from U.S. FDA for its Aurangabad (CSN) Facility.
- The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.
- Lupin specializes in pharmaceutical products across multiple therapy areas.
- The company has 15 state-of-the-art manufacturing sites and 7 research centers globally.
- Lupin is committed to improving patient health outcomes through its subsidiaries.